NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $36.08 +0.66 (+1.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$35.68▼$36.2450-Day Range$31.36▼$36.0852-Week Range$20.95▼$40.95Volume376,676 shsAverage Volume451,770 shsMarket Capitalization$1.18 billionP/E Ratio15.03Dividend YieldN/APrice Target$40.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Collegium Pharmaceutical alerts: Email Address Collegium Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside12.9% Upside$40.75 Price TargetShort InterestBearish21.80% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.94Based on 4 Articles This WeekInsider TradingSelling Shares$3.54 M Sold Last QuarterProj. Earnings Growth11.49%From $5.57 to $6.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector325th out of 936 stocksPharmaceutical Preparations Industry150th out of 436 stocks 2.2 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.Read more about Collegium Pharmaceutical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.80% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 0.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 2.7 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Collegium Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,540,796.00 in company stock.Percentage Held by InsidersOnly 3.98% of the stock of Collegium Pharmaceutical is held by insiders.Read more about Collegium Pharmaceutical's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 11.49% in the coming year, from $5.57 to $6.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 15.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.20.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 15.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 157.25.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Collegium Pharmaceutical Stock (NASDAQ:COLL)Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesJuly 25 at 1:21 AM | americanbankingnews.comAnalysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $40.75June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 11, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by JefferiesMay 29, 2024 | globenewswire.comCollegium to Participate in Jefferies Global Healthcare ConferenceMay 27, 2024 | investing.comCollegium Pharmaceutical Inc (COLL)May 14, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call TranscriptMay 13, 2024 | markets.businessinsider.comCollegium Pharmaceutical Enters ASR Agreement To Repurchase $35 Mln Of Common StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 13, 2024 | seekingalpha.comCollegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'May 13, 2024 | globenewswire.comCollegium Announces $35 Million Accelerated Share Repurchase ProgramMay 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | msn.comCollegium downgraded by Piper Sandler over valuationMay 11, 2024 | msn.comNeedham Downgrades Collegium Pharmaceutical (COLL)May 10, 2024 | finanznachrichten.deCollegium Pharmaceutical, Inc.: Collegium Reports First Quarter 2024 Financial ResultsMay 10, 2024 | markets.businessinsider.comDemystifying Collegium Pharmaceutical: Insights From 4 Analyst ReviewsMay 10, 2024 | finance.yahoo.comCollegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay PacketSee More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$40.75 High Stock Price Target$44.00 Low Stock Price Target$39.00 Potential Upside/Downside+12.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$2.40 Trailing P/E Ratio15.03 Forward P/E Ratio6.48 P/E GrowthN/ANet Income$48.15 million Net Margins16.46% Pretax Margin22.92% Return on Equity104.98% Return on Assets18.00% Debt Debt-to-Equity Ratio1.98 Current Ratio1.21 Quick Ratio1.14 Sales & Book Value Annual Sales$566.77 million Price / Sales2.08 Cash Flow$11.31 per share Price / Cash Flow3.19 Book Value$5.99 per share Price / Book6.02Miscellaneous Outstanding Shares32,720,000Free Float31,413,000Market Cap$1.18 billion OptionableOptionable Beta0.93 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 60)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)President, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 48)Executive VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 40)Executive VP, General Counsel, Chief Administrative Officer & Secretary Comp: $842.9kMr. Scott Dreyer (Age 52)Executive VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 63)M.D., Executive VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.Vice President of Investor RelationsMr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsSinovac BiotechNASDAQ:SVAStemline TherapeuticsNASDAQ:STMLInozyme PharmaNASDAQ:INZYNektar TherapeuticsNASDAQ:NKTRSpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 10,901 shares on 7/26/2024Ownership: 0.907%Allspring Global Investments Holdings LLCSold 1,947 shares on 7/26/2024Ownership: 0.133%Easterly Investment Partners LLCSold 7,000 shares on 7/25/2024Ownership: 0.130%SummerHaven Investment Management LLCBought 452 shares on 7/24/2024Ownership: 0.106%Louisiana State Employees Retirement SystemBought 300 shares on 7/24/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of 2024. Since then, COLL shares have increased by 17.2% and is now trading at $36.08. View the best growth stocks for 2024 here. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, May, 9th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by $0.04. The specialty pharmaceutical company had revenue of $144.92 million for the quarter, compared to the consensus estimate of $147.04 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 104.98% and a net margin of 16.46%. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Top institutional investors of Collegium Pharmaceutical include Assenagon Asset Management S.A. (1.11%), Bank of New York Mellon Corp (0.91%), Wedge Capital Management L L P NC (0.14%) and Allspring Global Investments Holdings LLC (0.13%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Scott Dreyer and Michael Thomas Heffernan. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA) and Pfizer (PFE). This page (NASDAQ:COLL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
